399 related articles for article (PubMed ID: 17679808)
21. Weight, the metabolic syndrome, and coronary heart disease in type 2 diabetes: associations among a national French sample of adults with diabetes-the ENTRED study.
Hillier TA; Fosse S; Balkau B; Simon D; Eschwège E; Fagot-Campagna A
J Cardiometab Syndr; 2006; 1(5):318-25. PubMed ID: 17679788
[TBL] [Abstract][Full Text] [Related]
22. Dyslipidemia and pediatric obesity.
Cook S; Kavey RE
Pediatr Clin North Am; 2011 Dec; 58(6):1363-73, ix. PubMed ID: 22093856
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular Disease Risk Assessment: Triglyceride/High-Density Lipoprotein versus Metabolic Syndrome Criteria.
Gharipour M; Sadeghi M; Nezafati P; Dianatkhah M; Sarrafzadegan N
J Res Health Sci; 2019 May; 19(2):e00442. PubMed ID: 31278212
[TBL] [Abstract][Full Text] [Related]
24. The prevalence, awareness, treatment, and control of dyslipidemia in northeast China: a population-based cross-sectional survey.
Zhang FL; Xing YQ; Wu YH; Liu HY; Luo Y; Sun MS; Guo ZN; Yang Y
Lipids Health Dis; 2017 Mar; 16(1):61. PubMed ID: 28330492
[TBL] [Abstract][Full Text] [Related]
25. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
26. Managing cardiovascular risk in overweight children and adolescents.
Dhuper S; Buddhe S; Patel S
Paediatr Drugs; 2013 Jun; 15(3):181-90. PubMed ID: 23580344
[TBL] [Abstract][Full Text] [Related]
27. Frequency of secondary dyslipidemia in obese children.
Korsten-Reck U; Kromeyer-Hauschild K; Korsten K; Baumstark MW; Dickhuth HH; Berg A
Vasc Health Risk Manag; 2008; 4(5):1089-94. PubMed ID: 19183757
[TBL] [Abstract][Full Text] [Related]
28. Successful control of dyslipidemia in patients with metabolic syndrome: focus on lifestyle changes.
Stone NJ
Clin Cornerstone; 2006; 8 Suppl 1():S15-20. PubMed ID: 16903165
[TBL] [Abstract][Full Text] [Related]
29. The lipid triad, or how to reduce residual cardiovascular risk?
Girard-Mauduit S
Ann Endocrinol (Paris); 2010 Mar; 71(2):89-94. PubMed ID: 20303470
[TBL] [Abstract][Full Text] [Related]
30. Pharmacotherapy for the metabolic syndrome.
Swislocki AL; Siegel D; Jialal I
Curr Vasc Pharmacol; 2012 Mar; 10(2):187-205. PubMed ID: 22022773
[TBL] [Abstract][Full Text] [Related]
31. Triglyceride-rich lipoproteins and HDL: what do recent trials tell us?
Stock J
Atherosclerosis; 2013 Jun; 228(2):329-31. PubMed ID: 23623013
[No Abstract] [Full Text] [Related]
32. [Lipid management--treatment goal and strategy].
Koshiyama H
Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303
[TBL] [Abstract][Full Text] [Related]
33. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
[TBL] [Abstract][Full Text] [Related]
35. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome.
Bray GA; Bellanger T
Endocrine; 2006 Feb; 29(1):109-17. PubMed ID: 16622298
[TBL] [Abstract][Full Text] [Related]
36. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease.
Windler E; Schöffauer M; Zyriax BC
Diab Vasc Dis Res; 2007 Jun; 4(2):136-42. PubMed ID: 17654448
[TBL] [Abstract][Full Text] [Related]
37. Metabolic Profile in Patients with Mild Obstructive Sleep Apnea.
Silva LOE; Guimarães TM; Luz GP; Coelho G; Badke L; Almeida IR; Millani-Carneiro A; Tufik S; Bittencourt L; Togeiro SM
Metab Syndr Relat Disord; 2018 Feb; 16(1):6-12. PubMed ID: 29148894
[TBL] [Abstract][Full Text] [Related]
38. Oxidative stress and adverse adipokine profile characterize the metabolic syndrome in children.
Kelly AS; Steinberger J; Kaiser DR; Olson TP; Bank AJ; Dengel DR
J Cardiometab Syndr; 2006; 1(4):248-52. PubMed ID: 17679810
[TBL] [Abstract][Full Text] [Related]
39. [How to treat dyslipidemia in patients with metabolic syndrome].
Soška V
Vnitr Lek; 2015; 61(7-8):721-4. PubMed ID: 26375703
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia.
Gündogan K; Bayram F; Capak M; Tanriverdi F; Karaman A; Ozturk A; Altunbas H; Gökce C; Kalkan A; Yazici C
Metab Syndr Relat Disord; 2009 Oct; 7(5):427-34. PubMed ID: 19754305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
